Interleukin Genetics' Q4 Revenues Fall 41 Percent; Firm Cautions on Financial Resources | GenomeWeb

NEW YORK (GenomeWeb News) – Interleukin Genetics' fourth-quarter revenues dropped 41 percent year over year, the company reported after the close of the market on Thursday, adding it has enough financial resources to last only through next month.

Revenues for the three months ended Dec. 31, 2012 totaled $339,057, down from $575,339 a year ago. Interleukin attributed the drop to decreased genetic testing revenue resulting from sales through the Amway Global sales channel.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: variation patterns in wheat lines, regulatory variation in Capsella grandiflora, and more.

A Rockefeller University researcher is using edited ants to explore complex biological systems, the New York Times writes.

There's a heritable aspect to how much time people spend online, the Los Angeles Times reports.

Stat News reports that Joseph Gulfo is another contender for FDA commissioner.